LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Начало・Списък с акции・Zai Lab Ltd ADR

Zai Lab Ltd ADR

Затворен

СекторЗдравеопазване

18.59 -2.26

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

18.45

Максимум

18.59

Ключови измерители
By Trading Economics
Приходи	-607K -51M
Продажби	-28M 100M
EPS	-0.46
Марж на печалбата	-51.215
Служители	1,784
EBITDA	4.1M -44M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+74.1% upside

Дивиденти
By Dow Jones
Следващи печалби	6.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-294M 2.1B
Предишно отваряне	20.85
Предишно затваряне	18.59

Настроения в новините

By Acuity

30%

70%

68 / 345 Класиране в Healthcare

Zai Lab Ltd ADR Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

24.05.2026 г., 23:46 ч. UTC

Пазарно говорене

Pullback in Oil Prices Could Temper Inflation Expectations -- Market Talk

24.05.2026 г., 23:45 ч. UTC

Пазарно говорене

Gold, Silver Rise on Hopes for U.S.-Iran Deal -- Market Talk

24.05.2026 г., 23:42 ч. UTC

Пазарно говорене

Mineral Resources Bull More Positive Post Site Visit -- Market Talk

24.05.2026 г., 23:34 ч. UTC

Пазарно говорене

Oil Falls Amid Prospects for Reopening of Strait of Hormuz -- Market Talk

24.05.2026 г., 23:11 ч. UTC

Пазарно говорене

RBNZ Likely to Stand Pat But Watch for Dissent -- Market Talk

24.05.2026 г., 22:26 ч. UTC

Придобивния, сливания и поглъщания

Beach Energy: La Bella 2 Will No Longer Be Drilled as Part of Equinox Campaign

24.05.2026 г., 22:25 ч. UTC

Придобивния, сливания и поглъщания

Beach Energy: Implied Transaction Value of Around A$130 Million After Tax

24.05.2026 г., 22:25 ч. UTC

Придобивния, сливания и поглъщания

Beach Energy: Royalty Payments Likely to Total Around A$140 Million Based on Resource Booking

24.05.2026 г., 22:24 ч. UTC

Придобивния, сливания и поглъщания

Beach Energy to Get Production Royalty of A$3.75/GJ in Deal

24.05.2026 г., 22:24 ч. UTC

Придобивния, сливания и поглъщания

Beach Energy to Get A$70 Million Cash Proceeds When Deal Completes

24.05.2026 г., 22:23 ч. UTC

Придобивния, сливания и поглъщания

Beach Energy Says Deal Includes Artisan Natural-Gas Discovery

24.05.2026 г., 22:23 ч. UTC

Придобивния, сливания и поглъщания

Beach Energy Sells 60% Operated Interest in VIC/L35 Block in Otway Basin

24.05.2026 г., 22:11 ч. UTC

Пазарно говорене

Oil Price Unlikely to Return to Pre-Conflict Levels This Year -- Market Talk

24.05.2026 г., 22:04 ч. UTC

Пазарно говорене

Oil Price Likely Lower, Equities Higher on Iran Deal Talks Progress -- Market Talk

23.05.2026 г., 08:20 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Financial Services Roundup: Market Talk

23.05.2026 г., 08:20 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

22.05.2026 г., 21:10 ч. UTC

Печалби

These Stocks Are Today's Movers: Dell, Apple, IBM, Estée Lauder, Futu, Rocket Lab, Workday, and More -- Barrons.com

22.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

22.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Financial Services Roundup: Market Talk

22.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

22.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

22.05.2026 г., 19:47 ч. UTC

Печалби

Nvidia Has a Plan to Get the Stock Moving Again -- Barrons.com

22.05.2026 г., 19:17 ч. UTC

Пазарно говорене

U.S. Natural Gas Retreats As Weather Outlook Cools -- Market Talk

22.05.2026 г., 19:10 ч. UTC

Пазарно говорене

Oil Futures Edge Up Ahead of U.S. Long Weekend -- Market Talk

22.05.2026 г., 18:54 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

22.05.2026 г., 18:54 ч. UTC

Пазарно говорене

Kroger Seen Narrowing Pricing Gap Versus Walmart -- Market Talk

22.05.2026 г., 18:38 ч. UTC

Пазарно говорене

Canada's Population Slowdown Hits Demand for Consumer Companies -- Market Talk

22.05.2026 г., 18:35 ч. UTC

Придобивния, сливания и поглъщания

IMAX Might Be Exploring a Sale. Who Could Be Buying. -- Barrons.com

22.05.2026 г., 18:09 ч. UTC

Пазарно говорене

Centralized Crypto Lending Slows in 1Q -- Market Talk

22.05.2026 г., 17:58 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Shows Signs of Picking Up -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Zai Lab Ltd ADR Прогноза

Ценова цел

By TipRanks

74.1% нагоре

12-месечна прогноза

Среден 32.4 USD 74.1%

Висок 44 USD

Нисък 21.6 USD

Според 4 анализатори от Wall Street, предложили 12-месечна ценова цел за Zai Lab Ltd ADR през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

4 ratings

Купи

Задържане

Продай

Според 4 анализатори, дали борсови рейтинги на Zai Lab Ltd ADR през последните 3 месеца.

Настроение

By Acuity

68 / 345 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.